A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
- 514 Downloads
The objectives of this study were to assess the toxicity and immunological response induced by the intra-dermal (i.d.) administration of MUC1-peptide-pulsed dendritic cells (DCs) in advanced pancreatic cancer patients. Patients with recurrent lesions or metastasis after surgery, and immunohistochemistry positive for MUC1 were treated in cohorts that received 3–6 × 106 DCs i.d. for three or four vaccines. Each vaccine was composed of autologus DCs pulsed with MUC1-peptide. Peripheral blood mononuclear cells (PBMCs) that harvested 2 weeks after the second immunization were compared with PBMCs obtained before treatment for immunological response. Serial ELISPOT assays of PBMCs for antitumor reactivity were performed. Three patients received all four vaccines, and four patients received three vaccines. These patients were evaluable for toxicity and immunological monitoring. There were no grade 3 or 4 toxicities associated with the vaccines or major evidence of autoimmunity. Interferon-γ and granzyme B ELISPOT assay reactivity increased significantly in 2 of 7 patients (P < 0.05). The administration of MUC1-peptide-pulsed DCs is non-toxic and capable of inducing immunological response to tumor antigen MUC1 in advanced pancreatic cancer patients. Additional studies are necessary to improve tumor rejection responses.
KeywordsDendritic cell MUC1 Immunotherapy Pancreatic cancer
This study was supported by the Key basic Grant in Biological Medicine (No.06DZ19009) from Shanghai, China and the Youth Grant (S-61) from the Fudan Univesity, Shanghai, China. We thank the pathologists in our hospital for skillful technical assistance, and we thank the haematologits for their help in collecting PBMCs.
Conflict of interest
- 2.Ries L, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Mariotto A, Feuer EJ, Edwards BK (2006) SEER cancer statistics review, 1975–2003. Bethesda. National Cancer Institute, MDGoogle Scholar
- 12.Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN (2008) Pilot study of mutant Ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 57(9):1413–1420PubMedCrossRefGoogle Scholar
- 25.Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ (1998) Successful adoptive cellular immuno-therapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J Immunol 160(1):334–344PubMedGoogle Scholar